Clinical Trials Browser

Not yet recruiting × Stomach Neoplasms × anlotinib × Clear all

NCT06222944 2024-01-25

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms